Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2022.09.08

Sai Life Sciences Manchester announces recruitment drive to increase scientific team by 20%

Sai Life Sciences Manchester announces recruitment drive to increase scientific team by 20%

Commences recruitment for 15 positions across analytical, chemistry, engineering and particle sciences departments

Sai Life Sciences, today announced plans to grow the scientific team at its site in Manchester, UK by 20% and commenced the process of recruitment for 15 positions across analytical, chemistry, engineering and particle sciences departments. View open positions.

Making the announcement, Dr Dean Edney, Global Head of Process R&D at Sai Life Sciences said, “In a little over two years since we began in Manchester, our team has established a formidable reputation for itself as a high-quality scientific unit that can solve complex chemistry challenges. Our growing list of global innovator clients is a strong validation of our success. The present recruitment drive is aimed at increasing our scientific capacity to better serve the growing demand.”

In July 2020, Sai Life Sciences opened a new Centre of Excellence in Process Chemistry R&D in Alderley Park, Manchester to help accelerate the NCE development programmes of its global innovator customers. This Centre has since grown to become a reliable partner to many innovator companies across the world, providing high quality chemistry, non-GMP material delivery, and successful technology transfer to its sites in India for scale-up.

Now, with a growing interest from its customers for clinical API supplies from Manchester, work is underway to set-up a GMP Kilo Lab at the Manchester site. Scheduled to be commissioned in Q4-2022, the new facility will be capable of delivering GMP drug substance and intermediates, with the GMP equipment engineered to provide containment down to 1µg/m3.

As part of the SaiNxt transformation initiative, the company has executed investments of US$110M in expanding into new geographies, augmenting its capacity and operations, while raising the bar for quality, compliance and performance.

Share article

More News

2026.03.27

Inside Sai Life Sciences’ Integrated R&D Campus: Accelerating Drug Development

In a recent feature published in R&D World, Sai Life Sciences’ Integrated R&D Campus in Hyderabad is showcased as a model for accelerating drug discovery and development through true scientific integration.In the article, Dr. B.V.N.B.S. Sarma, Senior Vice President – Discovery, highlights how co-locating multidisciplinary teams—from medicinal chemistry and biology to DMPK, developability, process development, […]
Read more

2026.03.27

Sai Life Sciences hosts Biotech Pitch Day 2026 at Boston Site

Sai Life Sciences successfully hosted its Biotech Pitch Day 2026 at its Boston-area site on March 19, bringing together a dynamic group of emerging biotech innovators, scientific leaders, and industry experts. The event was designed as a platform for early-stage biotech companies to showcase their science, strengthen visibility, and engage with potential collaborators across the […]
Read more

2026.03.25

Kudikunta Lake restoration completed, marking the revival of an urban water body

Kudikunta Lake in Kondapur, Hyderabad, was inaugurated on February 28th following the completion of restoration efforts undertaken by Sai Life Sciences as part of its Corporate Social Responsibility (CSR) initiative in collaboration with the Society for Advancement of Human Endeavour (SAHE). The event marked the culmination of several months of work to restore a previously […]
Read more

2026.03.10

AI-driven retrosynthesis integrated into Discovery Chemistry

Sai Life Sciences has entered into a collaboration with Chemical.AI, a technology company specialising in computer-aided synthesis design, to integrate an AI-driven retrosynthesis platform into its Discovery Chemistry workflows. The integration enables medicinal chemists to evaluate synthetic routes more rapidly and explore a broader set of feasible pathways during early-stage drug discovery. Retrosynthesis is a […]
Read more

2026.03.10

Structural Biology capabilities launched with X-Ray Crystallography

Sai Life Sciences has introduced integrated structural biology capabilities with the establishment of X-ray protein crystallography workflows to support structure-based drug discovery programs. The platform encompasses end-to-end protein engineering capabilities, including construct design, gene synthesis, and in-house recombinant protein expression and purification. These foundational steps enable generation of high-quality protein material suitable for structural and […]
Read more